Belite Bio (BLTE) stock

Market cap $6.6B

$159.56

-2.10%

Market closed. Prices as of today's close.

Quality Score

Below Average

In its industry

#90of 300

Biotech

Checks firing

1of 14

Choppy

From 52-week high

-20.2%

Above the 200-day

NextFeb 12, 2027 · In 133 days“User Fee Act (PDUFA) target action date of February 12, 2027”FDA decision date · 6-K, Aug 13

Follow BLTE's trial news. Pro members can get an alert when Belite Bio files news, and see its trials, share raises, and its CEO's filings.

Get an optional alert when BLTE files news on its trialsFree for 24 hours. No account needed.

Pipeline and cash

What's next for BLTE, and how long its cash lasts

From Belite Bio’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.

Next step the company has named

Feb 12, 2027In 133 days“User Fee Act (PDUFA) target action date of February 12, 2027”FDA decision date · 6-K, Aug 13

What it means: the date by which the FDA has said it aims to decide on the company’s application. The FDA can decide earlier, or extend the date.

A trial underway: PHOENIXPhase 3 · Active · 429 people · main data estimated Jun 30, 2027 · NCT05949593

1 more trial, 38 filings, for Pro members.

Cash runway Dec 31, 2025 balance sheet

$492M in cash

Fewer than four quarters of cash flow are on file.

What it means: a runway is counted only when each of the last four quarters used cash.

For Pro members: whether the cash lasts past the FDA date, the cash used each quarter, and the math.

Dilution on the horizon

No shelf registration of its own or at-the-market program on file in the last three years.

A shelf lets a company sell shares later; an at-the-market program sells them into the market over time. Neither is a sale by itself.

For Pro members: 4 raises and their amounts, and the share count against a year ago.

Insiders

CEO Yu-Hsin Lin sold 100,435 shares on Sep 8, under a planned sale. 25 more insider trades this year.

From their own Form 4 filings: buys and sales in the market, not awards or shares withheld for tax.

Get an optional alert when Yu-Hsin Lin buys or sells

For Pro members: every trade, and Yu-Hsin Lin’s 6 filings and quotes.

Get an optional alert before BLTE's FDA date

Free for 24 hours. No account needed. Then keep going with a free account.

See every upcoming FDA date →

Biotech dates

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.

DateStockDrug

In 28 daysFDA decisionIn 28 days · FDA decisionINOInovio PharmaceuticalsINO-3107INOInovio Pharmaceuticals · $125MINO-3107Under FDA review
In 39 daysANDA decisionIn 39 days · ANDA decisionNRXPNRX PharmaceuticalsDrug not namedNRXPNRX Pharmaceuticals · $123MDrug not namedA generic, under FDA review
In 51 daysFDA decisionIn 51 days · FDA decisionCAPRCapricor TherapeuticsDrug not namedCAPRCapricor Therapeutics · $520MDrug not namedUnder FDA review

8 more FDA dates and 114 trial data dates in the next 60 days. Pro members see every one, with the cash against its date and an optional alert before it. Get in free →

Quality Score

Why BLTE scores 4

Below AverageChoppy, 1 of 14 checks firingWhat the Quality Score means

Poor is below 0. Average starts at 6, Above Average at 11, Excellent at 15, and Exceptional at 20.

+2Long-term trend above a rising 200-⁠day average
+2Run-up 117% over 12 months

Chart checks adds
Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.

No effect today: Size, Growth, Dilution, Volatility, Cash flow, Persistence, and News.

What every line is worth, and the reason behind it, on BLTE and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 8:46 PM ET, at least 15 minutes behind. How we rank stocks.

What's next

Thu Oct 8: Innovate Retina Conference 2026Industry event · date confirmed.

Expected to report Mon Nov 9, after the close

1 more date ahead for Pro members: the conference

What would turn BLTE's score around: 4 things, for Pro members

Alert me when BLTE's Quality Score turns up

Free for 24 hours. No account needed. Then keep going with a free account.

Pro

Here is what Pro members see.

Every stock has a live page like this, BLTE included: the price in real time, the full chart, all 14 checks, and every line of its score.

AMD's page for Pro members on a phone, recorded live: the price changes as it trades, beside its Quality Score and its rank, with the bid and ask under it and a year of candles below — The same page for Pro members, on AMDThe live price and the full chart, with the Quality Score drawn under it and the line that drives it.

A Pro member's stock page for AMD: its Quality Score with its rank and the line driving it, the live price with the bid and ask, the chart checks, strength, and next earnings, and a year of candles with the 21 and 50-day averages and the Quality Score drawn under the chart — The same page for Pro members, on AMDThe live price and the full chart, with the Quality Score drawn under it and the line that drives it.

The Score tab on a phone: how AMD's Quality Score adds up from price action, the company, and signals, its rank, and the chart checks by group, trend, volume, tight range, and buying — Every line of the scoreWhat each part adds, and all 14 checks by group, on BLTE and every other stock.

The New alert form on a phone: watch one name, AMD, when its Quality Score is at least 20, sent by the bell on the site, a push notification, and email, with the Save alert button — Your own optional alertsPick what to watch, BLTE or your whole watchlist, and when: a Quality Score, a price, a filing. It comes by push, email, or the bell.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

The 14 checks

BLTE has 1 of 14 checks firing

One per group is shown here.

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Averages stacked in order, price near its high.

Volume1 of 3 shown

VOL VDU U/D VOL

Heavy volume on the run, quiet volume at rest.

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

The daily range is tight against its own recent history.

Buying1 of 3 shown

OBV+CLOSE HI SPRING

Closes near the high, and buyers step in on dips.

The other 10 checks on BLTE, and all 14 on every stock.Get in free →

Also on the chart

Not scored

Shown for reference. None of these counts toward the Quality Score: in our tests on 20 years of daily prices, none of them improved it.

RSI 1441.1
Above 30, below 50.
MACD (12, 26, 9)Below signal
Crossed below its signal line 12 sessions ago.
50-day average$165.68
The price is 3.7% below it.
200-day average$160.96
The price is 0.9% below it. The 50-day is above the 200-day, since Sep 4.
ADX 1412.1
Under 25, with +DI below -DI.
Support$159.00
Swing low from Aug 14, 0.4% below the price.
Resistance$160.55
Swing high from Dec 2, 2025, 0.6% above the price.
Bollinger Bands (20, 2)Inside
The bands run from $155.73 to $189.33.
Volume0.9x
Against its 20-day average, for the time of day.

Its industry

How BLTE ranks in Biotech

BLTE is #90 of 300 by Quality Score. The top three are shown with their scores, and more by name.

1KNSAKiniksa Pharmaceuticals International7/1418
2EXELExelixis7/1417
3AMRXAmneal Pharmaceuticals6/1417
BIIBBiogenOpen for its score
BIOABioAge LabsOpen for its score
BMRNBioMarin PharmaceuticalsOpen for its score
BNTXBioNTechOpen for its score
90BLTEBelite Bio1/144

When does BLTE report earnings, and what happens after?

Expected to report Mon Nov 9, after the close (in 38 days). Not yet confirmed by the company.

Filings

Who is trading BLTE

BLTE insider trades

One insider sold $2.9M across 13 filings in the last 6 months. No open-⁠market buys on record. The newest:

SellHendrik Peter Scholl$707KChief Medical Officerat $145.43 on Jun 18, filed Jun 22

SellHendrik Peter SchollChief Medical Officer$707Kat $145.43 on Jun 18, filed Jun 22

All 13 insider filings on BLTE from the last six months, for Pro members.Get in free →

An insider has two business days to file a Form 4, so the trade is already days old when it becomes public. Shown as filed, with no delay.

The company

About Belite Bio

Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.

41 employeesbelitebio.com

Pro

Every line of the score, on every stock.

Real-time prices, no delay
Every line of BLTE's score, with the points and the reason
All 14 checks on BLTE and on all 3,243 stocks
Every stock ranked, with the chart
Every filing, and optional alerts on BLTE

BreakawayJun 22Hendrik Peter Scholl sold BLTE$707K at $145.43, filed Jun 22

What a filing on BLTE would have sent. Alerts are optional.

See all 14 checks on BLTEFree for 24 hours. No account needed. Then keep going with a free account.

Questions

Straight Answers.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, trial included, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Where does the data come from?

Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.

Do I need an account?

Not for the first 24 hours. Tap any green button and you're in, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.

Is this investment advice?

No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes. Filings are shown as filed, because a disclosure is already days or weeks old when it becomes public. Earnings dates and past reactions are settled sessions.